Trial Profile
A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Acronyms MERIT
- Sponsors ALK-Abello
- 26 Feb 2019 According to an ALK-Abello media release, the company announced that the post-hoc analysis of this trial were were presented for the first time at this year Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI).
- 26 Feb 2019 Results of post-hoc analysis published in the ALK-Abello Media Release
- 25 Feb 2019 Results of a post-hoc analysis assessing the effect of treatment with SQ-HDM SLIT-tablet on sleep in HDM allergic rhinitis, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology